Stock listing

Neuroscientific Biopharmaceuticals Ltd.

Selected listing: NSB · ASX · AUD · AU

Neuroscientific Biopharmaceuticals Ltd. (ASX:NSB), Health Technology. Latest release Sep 30, 2026: Leading CRO Appointed for Phase 2 Crohn's Trial.

NSB:ASXAUDAUUpdated September 25, 2026
Neuroscientific Biopharmaceuticals Ltd. logo
Ticker
ASX:NSB
Asset type
Stock
Sector
Health Technology
Industry
Biotechnology
Exchange
ASX
Currency
AUD

About Neuroscientific Biopharmaceuticals Ltd.

The company focuses on developing innovative biopharmaceutical products aimed at addressing neurological disorders. Its commitment to research and development positions it within the growing biopharmaceutical sector.

Latest news from Neuroscientific Biopharmaceuticals Ltd.

Leading CRO Appointed for Phase 2 Crohn's Trial

September 30, 2026

2026 Annual Report & Appendix 4E

August 25, 2026

Remarkable Results from Patients treated with StemSmart

May 25, 2026

Half Yearly Report and Accounts

February 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

All Neuroscientific Biopharmaceuticals Ltd. news →

Research Neuroscientific Biopharmaceuticals Ltd.

Neuroscientific Biopharmaceuticals Ltd. company profile

View the public company page for Neuroscientific Biopharmaceuticals Ltd. on 6ix.

Neuroscientific Biopharmaceuticals Ltd. news

Read company news and market updates connected to Neuroscientific Biopharmaceuticals Ltd..

Neuroscientific Biopharmaceuticals Ltd. investor events

Find investor webinars, events, and replay context for Neuroscientific Biopharmaceuticals Ltd..